TY - JOUR
T1 - Bromocriptine reduces steatosis in obese rodent models
AU - Davis, Lisa M.
AU - Pei, Zhengtong
AU - Trush, Michael A.
AU - Cheskin, Lawrence J.
AU - Contoreggi, Carlo
AU - McCullough, Karen
AU - Watkins, Paul A.
AU - Moran, Timothy H.
PY - 2006/9/1
Y1 - 2006/9/1
N2 - Background/Aims: Obesity is a risk factor for glucose intolerance, steatosis, and oxidative stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti-obesity, insulin-sensitizing, lipolytic, and antioxidant properties. We, therefore, hypothesized that bromocriptine would improve markers of nonalcoholic fatty liver disease in obese rodent models. Methods: We performed a randomized, controlled experiment in genetically obese fatty Zucker rats and diet-induced obese rats to assess for behavioral and peripheral anti-obesity actions of bromocriptine (10 mg/kg) that would improve nonalcoholic fatty liver disease. Results: Behaviorally, food intake decreased and locomotor activity increased in bromocriptine-treated fatty Zucker and dietary-induced obese rats. Peripherally, liver triglycerides were significantly reduced and hepatic manganese superoxide dismutase significantly increased in bromocriptine-treated fatty Zucker and diet-induced obese rats compared to controls. Blood glucose was significantly lower in bromocriptine-treated Zucker rats compared to fatty controls and was no different than that of lean controls. Conclusions: Improvements in obesigenic behaviors, glucose tolerance, hepatic lipid accumulation, and mitochondrial oxidative stress observed in genetically obese and diet-induced obese rodents indicate that bromocriptine may be promising as a broad-based therapy for nonalcoholic fatty liver disease.
AB - Background/Aims: Obesity is a risk factor for glucose intolerance, steatosis, and oxidative stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti-obesity, insulin-sensitizing, lipolytic, and antioxidant properties. We, therefore, hypothesized that bromocriptine would improve markers of nonalcoholic fatty liver disease in obese rodent models. Methods: We performed a randomized, controlled experiment in genetically obese fatty Zucker rats and diet-induced obese rats to assess for behavioral and peripheral anti-obesity actions of bromocriptine (10 mg/kg) that would improve nonalcoholic fatty liver disease. Results: Behaviorally, food intake decreased and locomotor activity increased in bromocriptine-treated fatty Zucker and dietary-induced obese rats. Peripherally, liver triglycerides were significantly reduced and hepatic manganese superoxide dismutase significantly increased in bromocriptine-treated fatty Zucker and diet-induced obese rats compared to controls. Blood glucose was significantly lower in bromocriptine-treated Zucker rats compared to fatty controls and was no different than that of lean controls. Conclusions: Improvements in obesigenic behaviors, glucose tolerance, hepatic lipid accumulation, and mitochondrial oxidative stress observed in genetically obese and diet-induced obese rodents indicate that bromocriptine may be promising as a broad-based therapy for nonalcoholic fatty liver disease.
KW - Bromocriptine
KW - Dopamine D2 agonist
KW - NAFLD
KW - Nonalcoholic fatty liver disease
KW - Obesity
UR - http://www.scopus.com/inward/record.url?scp=33746499106&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746499106&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2006.03.019
DO - 10.1016/j.jhep.2006.03.019
M3 - Article
C2 - 16780999
AN - SCOPUS:33746499106
VL - 45
SP - 439
EP - 444
JO - Journal of Hepatology
JF - Journal of Hepatology
SN - 0168-8278
IS - 3
ER -